Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Price Breaks Above 200 Day Moving Average – Here’s Why

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s stock price crossed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $9.65 and traded as high as $10.0699. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $9.9699, with a volume of 73,749 shares.

Wall Street Analyst Weigh In

A number of equities analysts have commented on SGIOY shares. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a report on Thursday, October 15th. Three analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, the stock presently has a consensus rating of “Strong Buy”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company’s 50-day moving average is $9.23 and its 200-day moving average is $9.65. The firm has a market cap of $16.10 billion, a price-to-earnings ratio of 10.51, a price-to-earnings-growth ratio of 3.41 and a beta of 0.10. The company has a current ratio of 1.14, a quick ratio of 1.00 and a debt-to-equity ratio of 0.01.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last released its quarterly earnings data on Thursday, October 29th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.11 billion. Shionogi & Co., Ltd. Unsponsored ADR had a return on equity of 14.32% and a net margin of 37.95%. Equities research analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.83 earnings per share for the current year.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that researches, develops, manufactures and markets prescription medicines. Founded in Osaka in 1878, it has grown from a pharmaceutical wholesaler into a research-focused drugmaker.

The company has a particular focus on infectious diseases, including HIV, influenza and COVID-19, and also works in areas such as pain and central nervous system disorders. Its products include Xofluza, an influenza treatment, and ensitrelvir, an oral COVID-19 antiviral marketed in Japan as Xocova.

Shionogi serves patients in Japan and international markets through its own operations and collaborations with other pharmaceutical companies.